10. Role of high dimensional technology in preeclampsia (omics in preeclampsia).
Metabolomics
Proteomics
epigenomics
genomics
microbiomics
omics
preeclampsia
transcriptomics
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
18 Nov 2023
18 Nov 2023
Historique:
received:
01
06
2023
revised:
05
07
2023
accepted:
06
08
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
Preeclampsia is a pregnancy-specific disease that has no known precise cause. Integrative biology approach based on multi-omics has been applied to identify upstream pathways and better understand the pathophysiology of preeclampsia. At DNA level, genomics and epigenomics studies have revealed numerous genetic variants associated with preeclampsia, including those involved in regulating blood pressure and immune response. Transcriptomics analyses have revealed altered expression of genes in preeclampsia, particularly those related to inflammation and angiogenesis. At protein level, proteomics studies have identified potential biomarkers for preeclampsia diagnosis and prediction in addition to revealing the main pathophysiological pathways involved in this disease. At metabolite level, metabolomics has highlighted altered lipid and amino acid metabolisms in preeclampsia. Finally, microbiomics studies have identified dysbiosis in the gut and vaginal microbiota in pregnant women with preeclampsia. Overall, omics technologies have improved our understanding of the complex molecular mechanisms underlying preeclampsia. However, further research is warranted to fully integrate and translate these omics findings into clinical practice.
Identifiants
pubmed: 37995432
pii: S1521-6934(23)00134-7
doi: 10.1016/j.bpobgyn.2023.102427
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102427Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicts of interest to declare.